论文部分内容阅读
目的研究脆性组氨酸三联体基因(FHIT)在膀胱移行细胞肿瘤中的表达及其临床意义。方法用免疫组化法检测60例术前未经化疗、放疗和免疫治疗的膀胱移行细胞肿瘤和20例膀胱非肿瘤性病变的FHIT蛋白的表达。结果FHIT蛋白在膀胱病变的肿瘤与非肿瘤之间的表达有显著性差异(P<0.05)。FHIT蛋白在膀胱移行细胞肿瘤不同分级中随恶性程度的增高,表达减少,有显著的统计学意义(Spearman相关分析,P<0.01);在膀胱移行细胞癌不同临床分期中随分期的增高,表达减少,但无统计学差异(P>0.05)。结论FHIT与膀胱肿瘤移行细胞癌的发生发展有关,可望成为一种新的预后指标用于临床监测。
Objective To study the expression of FHIT in bladder transitional cell carcinoma and its clinical significance. Methods Immunohistochemical method was used to detect the expression of FHIT protein in 60 cases of BTCC and 20 cases of non-neoplastic bladder tumor without chemotherapy, radiotherapy and immunotherapy. Results There was a significant difference in the expression of FHIT protein between bladder tumor and non - tumor (P <0.05). The expression of FHIT protein in different grades of transitional cell carcinoma of the bladder increased with the degree of malignancy, the expression decreased, with significant statistical significance (Spearman correlation analysis, P <0.01); in different stages of bladder transitional cell carcinoma Reduced, but no statistical difference (P> 0.05). Conclusion FHIT is associated with the occurrence and development of transitional cell carcinoma of the bladder and is expected to become a new prognostic indicator for clinical monitoring.